Benjamin Edwards’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Benjamin Edwards's CRSP Position: Q3 2026 in Review
Benjamin Edwards increased its CRISPR Therapeutics (CRSP) stake by 0.41% in Q3 2026, buying an estimated $12.1K and bringing the position to 54,712 shares worth $3.03M. The position accounts for 0.03% of the portfolio, ranked #471.
Benjamin Edwards first reported a position in CRSP in Q1 2019 and has held it in 31 quarters since. The position peaked at $3.51M in Q3 2025. 413 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Benjamin Edwards held 54,712 shares of CRISPR Therapeutics worth $3.03M as of Q3 2026.
- Benjamin Edwards bought 224 CRISPR Therapeutics shares in Q3 2026, an estimated $12.1K.
- CRISPR Therapeutics made up 0.03% of Benjamin Edwards's portfolio in Q3 2026, its #471 holding.
- Benjamin Edwards first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 31 quarters since.
- Benjamin Edwards's CRISPR Therapeutics position peaked at $3.51M in Q3 2025.
- 413 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Benjamin Edwards's 13F filing for Q3 2026, filed 12 Nov 2026.